Emerres® – A low cost1-3, bioequivalent alternative to Levonelle 1500®4

  • Emerres® is an emergency contraceptive pill which contains 1.5mg levonorgestrel3
  • Emerres® contains the same active ingredients and is bioequivalent to Levonelle 1500®, therefore, following appropriate patient assessment and review, it may be prescribed in place of Levonelle 1500®4–6
  • Each pack of Emerres® contains a single tablet of emergency contraception3

Clinical studies indicate that Emerres® may prevent 84–85% of expected pregnancies if taken within 72 hours of unprotected sexual intercourse.5

  • Emerres® emergency contraception should be offered after sexual intercourse if:
    • No form of contraception was used5,7
    • Withdrawal method was used7
    • Barrier method failed (e.g. condom tore or slipped off, or the diaphragm/cervical cap was incorrectly inserted, became dislodged, was damaged or removed less than 6 hours after intercourse)7
  • NICE guideline states:

    Offer emergency contraception to all women after sexual intercourse if:

    • The woman is using the combined oral contraceptive pill, combined contraceptive patch, contraceptive vaginal ring, progestogen-only pill, or progestogen-only implant when:
    • There is a failure to use additional contraceptive precautions when starting the method, and unprotected sexual intercourse (UPSI) or barrier failure occurs during the time that additional precaution is required
    • Unprotected sexual intercourse or barrier failure occurs during, or in the 28 days following the use of potent liver enzyme-inducing drugs (such as rifampicin, phenytoin, carbamazepine)
  • If vomiting occurs within 3 hours of taking the tablet, another tablet should be taken immediately5
  • After using emergency contraception it is recommended that patients use a local barrier method (e.g. condom, diaphragm, spermicide or cervical cap) until the next menstrual period starts5
  • The use of Emerres® does not contraindicate the continuation of regular hormonal contraception5

Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.

Summary of Product Characteristics and Patient Information Leaflet
Summary of Product Characteristics:
https://www.medicines.org.uk/emc/product/9569/smpc

Patient Information Leaflet:
https://www.medicines.org.uk/emc/product/9569/pil

Additional Prescriber Resources
The full NICE Clinical Knowledge Summary for Emergency Contraception may be found here

References

  1. Data on File: Contraceptives Cost Saving Data. Feb 2019;
  2. MIMS. Emerres. Available at: https://www.mims.co.uk/drugs/contraception/emergency-contraceptives/emerres (accessed June 2020);
  3. MIMS. Levonelle 1500 (Bayer plc). Available at: https://www.mims.co.uk/drugs/contraception/emergency-contraceptives/levonelle-1500 (accessed June 2020);
  4. MHRA. UK PAR Emerres 1.5mg Tablet. December 2014. Available at: https://mhraproductsproduction.blob.core.windows.net/docs/0f60e25dbc2b59d4f5b28a5320b2664a18da6b7e (accessed June 2020);
  5. Morningside Healthcare Ltd. Emerres 1.5 mg tablet. May 2020. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9569/smpc (accessed June 2020);
  6. Bayer plc. Levonelle 1500 microgram tablet. Summary of Product Characteristics. November 2018. Available at: https://www.medicines.org.uk/emc/medicine/16887/smpc (accessed June 2020);
  7. NICE. Contraception – emergency. March 2020. Available at: https://cks.nice.org.uk/contraception-emergency (accessed June 2020).

Levonelle 1500® chosen as a comparator as it is the license reference product for Emerres®.4